Genmab — November 2025
-
@Plimsoller looks like only 6 again, i imagine you were probably hoping for something on epco, but this is nice i would say
-
ASH25 LBA-6
Abstract Title : Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice
of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients
(Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
https://meetings-api.hematology.org/api/abstract/vmpreview/304640 Spectacular
... -
@E L Yes, it was epco I had in mind when asking a while back, but this will do
Let's hope for a good run up to ASH this year, and an even stronger finish in 2025. -
Den nyhed er vel kursdrivende, så jeg tror at de kommer med den når data er modne til offentliggørelse? Er der andre bud på det?
-
BOFA -GMAB top SMID pick with high conviction in 3 26E catalysts for >$5bn peak https://x.com/semodough/status/1993330204442316888
-
-
Ret beset ved vi vel ikke noget, men det hedder, at "Overall Survival (OS) is the primary endpoint in USA and in China, with the analysis population including all randomized participants.". Så måske den slags analyser også bare tager længere tid...
-
25/11 21:02 Euroinvestor "Genmab: Stemningen er vendt - Investoren Helge Larsen sætter ord på udviklingen af Genmab aktien" 2 min https://www.euroinvestor.dk/nyheder/genmab-stemningen-er-vendt
-
Blood: Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives https://ashpublications.org/blood/article/146/22/2617/548279/Better-together-epcoritamab-boosts-R2-in-FL
-
Impressive: The efficacy appeared impressive: ORR 96% and CR 88% that were maintained even in patients with high-risk features. Minimal residual disease negativity rate was 86%. Survival outcomes at 2 years look favorable as well: remaining in CR for the duration of the study, 82% = KYSO...
-
Ugens grafik: Kinas antibody-udvikling stormer frem
Ugens grafik handler om et af de emner, der langsomt men sikkert er på vej frem. Et emne der får mere og mere opmærksomhed
Økonomisk Ugebrev (ugebrev.dk)
-
Så vi kan forvente at Kina kommer ind fra højre med mange præperater vi evt. skal konkurrere med
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind